Skip to content
  • About
  • Contact
  • Our Staff
  • Advertise
US Pharma Marketing Logo

US Pharma Marketing

  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A

DTC Advertising

FDA’s Crackdown on Pharma’s Digital Marketing: What the Warning Letters to Lilly, Novo, and Novartis Signal for the Future of DTC Advertising
Posted in
  • Digital Transformation
  • Industry Landscape

FDA’s Crackdown on Pharma’s Digital Marketing: What the Warning Letters to Lilly, Novo, and Novartis Signal for the Future of DTC Advertising

For years, pharmaceutical marketing teams have operated in a gray zone—especially on social media. Branded content, … FDA’s Crackdown on Pharma’s Digital Marketing: What the Warning Letters to Lilly, Novo, and Novartis Signal for the Future of DTC AdvertisingRead more

by Gurinder Khera•November 4, 2025November 4, 2025•0

Recent Posts

  • Biopharma Layoffs: Optimizing Sales Teams Amid Workforce Shifts
  • Competitive Intelligence Surge: Elevating Pharma Marketing Insights
  • Eli Lilly Trades AI Access for Biotech Data to Drive Precision Marketing in Obesity and Alzheimer’s
  • FDA’s Crackdown on Pharma’s Digital Marketing: What the Warning Letters to Lilly, Novo, and Novartis Signal for the Future of DTC Advertising
  • Top-Selling Biotech Drugs & Revenue Forecasts: Tracking Blockbusters and the Road Ahead

Recent Comments

No comments to show.
Copyright © 2025 US Pharma Marketing.
Powered by WordPress and HybridMag.
  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A